Daily Stock Analysis, HZNP, Horizon Pharma PLC, priceseries

Horizon Pharma PLC. Daily Stock Analysis
Stock Information
Open
92.20
Close
91.45
High
93.97
Low
90.88
Previous Close
91.62
Daily Price Gain
-0.17
YTD High
96.54
YTD High Date
Feb 24, 2021
YTD Low
70.15
YTD Low Date
Jan 27, 2021
YTD Price Change
18.91
YTD Gain
26.07%
52 Week High
96.54
52 Week High Date
Feb 24, 2021
52 Week Low
30.40
52 Week Low Date
Apr 15, 2020
52 Week Price Change
59.50
52 Week Gain
186.23%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 20. 2017
10.84
Jul 27. 2017
12.82
26 Trading Days
18.28%
Link
LONG
Sep 27. 2017
12.51
Oct 16. 2017
13.61
13 Trading Days
8.79%
Link
LONG
Feb 28. 2018
14.58
Mar 13. 2018
15.34
9 Trading Days
5.21%
Link
LONG
May 11. 2018
14.25
Jun 25. 2018
17.18
30 Trading Days
20.57%
Link
LONG
Aug 7. 2018
18.16
Aug 23. 2018
19.98
12 Trading Days
10.01%
Link
LONG
Jan 31. 2019
21.49
Feb 19. 2019
22.80
12 Trading Days
6.11%
Link
LONG
Dec 12. 2019
32.84
Jan 6. 2020
35.55
15 Trading Days
8.25%
Link
LONG
Apr 14. 2020
31.56
Jun 3. 2020
48.94
35 Trading Days
55.07%
Link
LONG
Jun 18. 2020
48.43
Jul 13. 2020
55.67
16 Trading Days
14.95%
Link
LONG
Jul 28. 2020
59.28
Aug 24. 2020
73.48
19 Trading Days
23.95%
Link
LONG
Feb 1. 2021
77.04
Feb 22. 2021
84.88
14 Trading Days
10.18%
Link
Company Information
Stock Symbol
HZNP
Exchange
NasdaqGS
Company URL
http://www.horizonpharma.com
Company Phone
011-353-1-772-2100
CEO
Timothy P. Walbert
Headquarters
-
Business Address
CONNAUGHT HOUSE, 1ST FLOOR, 1 BURLINGTON ROAD, DUBLIN, IRELAND 4
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001492426
About

Horizon Pharma Plc engages in the research, development, and market of pharmaceutical products. Its medicines intend to treat arthritis, inflammation, and orphan diseases. It distributes under the following brands: Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid, Ravicti, Rayos, and Vimovo. The company was founded on December 20, 2011 and is headquartered in Dublin, Ireland.

Description

Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally. The company's marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout. Its products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The company has collaboration agreements with Fox Chase Cancer Center to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors for use in the treatment of various forms of cancer; and Alliance for Lupus Research (ALR) to study the effect of RAYOS on the fatigue experienced by systemic lupus erythematosus (SLE) patients. Horizon Pharma Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.